More recently, 5‐LO has been identified as a potential therapeutic target for conditions such as rheumatoid arthritis,45, 46 atherosclerosis,47, 48, 49 Alzheimer's disease50 and leukemia stem cells.51, 52 However, zileuton has poor pharmacokinetic properties and liver toxicity issues, whereas the Cys‐LT1 receptor antagonists only target the cys‐LTs and not the LTB4 receptors that play an important role in several pathologies. This evidence concerns the gene ALOX5 and leukemia.